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ABSTRACT
Background: The prevalence of  diabetes mellitus is 
rising in Nigeria and its complications present an 
immense public health burden.
Objective(s): The objective of  this discourse is to 
review the state of  diabetes care in Nigeria with focus 
on the needs, priorities and recommendations, which 
should guide our clinicians. It will discuss the definition, 
pattern, landmark Nigerian studies on diabetes care, 
matters arising, morbidity/mortality and proposed 
strategies for improving diabetes care in Nigeria.
Methods (Data Sources /extraction): The data search 
used in this review covered studies published from 
1959-2010, obtained from prevalence studies, hospital 
statistics, registry reports, landmark hospital-based 
studies, recent international conference proceedings, 
world health reports, government estimates, United 
Nations resolutions on diabetes, international diabetes 
federation (IDF) declarations and clinical practice 
guidelines.
The medline database, the internet (e-medicine, 
medscape resource etc), journal articles, World Health 
and international diabetes federation (IDF) 
monographs were used.
Results: The rising prevalence of  diabetes as well as its 
associated morbidity / mortality, preventive measures 
and effective treatments are well recognized. However, 
in practice this knowledge is under- utilized because 
only about a third of  Nigerians living with diabetes 
achieve optimum targets (glycaemic control, blood 
pressure, lipids and weight).
Conclusion: Most Nigerians living with diabetes have 
suboptimal control, are hypertensives and have chronic 
complications. Improved quality of  care and treatment-
to-target is recommended to reduce diabetes-related 
morbidity and mortality. 






Diabetes mellitus is the commonest endocrine-metabolic 
disorder characterized by chronic hyperglycaemia giving 
rise to the risk of  microvascular (retinopathy, nephropathy, 
and neuropathy) and macrovascular (ischaemic heart 
1disease, stroke and peripheral vascular disease) damage , 
with associated reduced life expectancy and diminished 
quality of  life.
Recent estimates indicate there were 171 million people in 
the world with diabetes in the year 2000 and this is 
1 projected to increase to 366 million by 2030. This increase 
in prevalence is expected to be more in the Middle Eastern 
1crescent, Sub-Saharan Africa and India .
In Africa, the estimated prevalence of  diabetes is 1% in 
rural areas, up to 7% in urban sub-Sahara Africa, and 
between 8-13% in more developed areas such as South 
2 Africa and in population of  Indian origin.
The prevalence in Nigeria varies from 0.65% in rural 
3 Mangu (North) to 11% in urban Lagos (South) and data 
from the World Health Organization (WHO) suggests that 
Nigeria has the greatest number of  people living with 
1diabetes in Africa.
REVIEW OF SOME NIGERIAN STUDIES
Cobban was one of  the first to remark on the relative rarity 
4of  diabetes in UCH, Ibadan in the 1950s.
3[1997 National NCD survey:] Akinkugbe et al  in their 
National survey of  Non-communicable diseases in Nigeria 
(1997) documented the national prevalence of  diabetes 
(age-adjusted) to be 2.2% with male: female ratio of  1:1.1 
and a significant increase in prevalence with age. Thus 
below the age of  45 years, crude prevalence in males was 
1.6% and 1.9% in females, rising to 5.4% in males and 5.6% 
in females  after the age of  45years reflecting a threefold 
increase in each gender. The same survey estimated that 
not less than 1.05% million Nigerians were likely to be 
diabetic with only about 225,000 being aware of  their 
condition and about 198,000 receiving treatment. The 
above figures were most probably higher because Nigerians 
bellow the age of  15years were not included in the survey 
and results were not available for some states due to 
technical and logistic reasons.
PATTERN OF DIABETES IN THE NIGER DELTA REGION 
5A follow-up cross-sectional study  of  people living with 
diabetes in Rivers state (a core Niger Delta state not 
included in the 1997 survey) revealed diabetes to be a 
substantial health problem with 780 type 2 diabetics 
presenting at diagnosis with the following complications 
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viz neuropathy 439 (56.3%), erectile dysfunction 283 (36.3%), 
nephropathy 72 (9.2%) and retinopathy 57(7.3%) ( table 1).
UNDIAGNOSED DIABETES
It is a fact that type 2 diabetes has an asymptomatic pre-
clinical phase which is not benign, thus underscoring the 
need for primary prevention and population screening in 
order to achieve early diagnosis and treatment.
The prevalence of  undiagnosed diabetes has been found to 
6range from 4.76%  in one study of  outpatients attending a 
7family practice clinic to as high as 18.9%  in another study. In 
the latter study, the prevalence of  diabetes was found to be 
higher by as much as 68% in persons of  a higher socio-
economic status. 
Earlier studies reported lower prevalence rates for 
undiagnosed diabetes in the population. Nyenwe et al 
8reported 2.8%  in Port Harcourt while a study in Lagos 
9reported as low as 1.7%  in Lagos metropolis in 1988.
DIABCARE NIGERIA MULTI-CENTRE STUDY 
10In 2008, the landmark Diabcare Nigeria study  was 
prospectively conducted across seven tertiary health centers 
in Nigeria with the objective of  assessing the clinical and 
laboratory profile, evaluating the quality of  care of  Nigerian 
diabetics with a view to planning improved diabetes care.
The clinical parameters studied include: types of  diabetes, 
anthropometry, blood pressure, chronic complications of  
diabetes and treatment types. Laboratory data assessed 
include: fasting plasma glucose (FPG), 2 Hour post-prandial 
(2-HrPP), glycated haemoglobin (HbA1c), urinalysis, serum 
lipids, electrolytes, urea and creatinine.
A total of  531 patients, 209(39.4%) males and 322(60.6%) 
females enrolled. Mean age of  the patients was 57.1±12.3 
years with mean duration of  diabetes of  8.8±6.6 years. 
Majority (95.4%) had type 2 diabetes mellitus compared to 
type 1 (4.6%), p < 0.001. The mean FPG, 2-HrPP glucose and 
HbA1c were 8.1±3.9mmol/L, 10.6±4.6mmol/L and 
8.3±2.2 % respectively. Only 170(32.4%) and 100(20.4%) 
patients achieved the ADA and IDF glycaemic targets 
respectively. Most patients (72.8%) did not practice self-
monitoring of  blood glucose.  Hypertension was found in 
322(60.9%), with mean systolic BP of  142.0±23.7mmHg and 
mean diastolic BP of  80.7±12.7mmHg (see table 2 and 3). 
The Diabetes complications found were peripheral 
neuropathy 59.2%, retinopathy 35.5%, cataracts 25.2%, 
Cerebrovascular disease 4.7%, diabetic foot ulcers 16.0% and 
nephropathy 3.2%. (See table 2 and 3)
It was obvious from that survey that the status of  Diabetes 
Care in terms of  glycaemic control, control to goal of  other 
cardiovascular risk factors, management practices and 
presence of  late complications of  diabetes were below the 
optimum expected.
11Arije et al  reported that satisfactory systolic and diastolic 
blood pressure control was obtained in only 38.5% and 42.2% 
of  some Nigerian patients attending a tertiary health facility, 
respectively.
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Dyslipidaemia is also common. In a study of  600 patients 
with type2 diabetes, up to 89% had lipid abnormalities. 
Elevated LDL-C, TCHOL, TG and reduced HDL-C were 
noted in 74%, 42%, 13%, and 53% respectively of  the study 
subjects. The commonly noted combined lipid abnormalities 
were elevated TG and reduced HDL-C. Only a small 
proportion  (8%) of  the subjects with dyslipidaemia were on 
12treatment for it .
PROGNOSTIC INDICES OF DIABETES MORTALITY
From January through December 2006, subjects with 
diabetes mellitus (DM) in a tertiary hospital in Nigeria were 
prospectively studied after admission to assess their short-
13term outcome which was defined as death.  The total 
mortality, causes of  death, associated complications and 
duration of  hospital stay were noted. The predictive factors 
for DM morbidity were evaluated using chi test, logistic 
regression. Student's t test was computed for quantitative data.
A total of  1,327 subjects were admitted to the Medical wards 
for the duration of  the study and the crude death rate was 11%. 
DM related admissions made up 206 (15%) of  all the medical 
admissions and the case fatality rate was 16% (33). The most 
common reasons for DM admission were hyperglycaemic 
emergencies (HE), 88 (40%) and hypertension, 44 (21%). The 
most common causes of  deaths were HE, 15 (46%) and DM 
foot ulcers (DFU), 10 (30%) while DFU and cerebrovascular 
disease (CVD) had the highest case fatality rates of  28% and 
25% respectively. DFU had the most prolonged duration of  
admission ranging from 15-122 days. DFU, CVD and type 2 
DM were highly predictive of  fatal outcomes. The odds ratio 
and 95% CI for these factors were 4.5 (1.512.7), 3.0 (0.9 9.92 
and 3.1 (0.714) respectively. (see table 4).
In a similar study on mortality in in-patients in a tertiary 
hospital, diabetic patients constituted 10.4% of  all hospital in-
patients over a 10 year period. The case fatality for the 
patients with diabetes was 17.2% with acute diabetic 
complications viz keto-acidosis, hyperglycaemic 
5Table 1: Pattern of Diabetes in Niger Delta Region
Parameters  Type 1 Type 2 Other types GDM 
Total Number (n)% 25(3.0%) 780(94%) 10 (1.2%) 15(1.8%) 
Positive family history of  DM (1st 
degree) 
3 (12%) 408 (52.3%) Nil  8 (53.3%) 
Polyuria 25(100%) 713 (91.4%) 10(100%) 11(73.3%) 
Polydipsia 25(100%) 720(92.3%) 10(100%) 11(73.3%) 
Polyphagia 12(48%) 392(50.3%) - - 
Lassitude  25(100%) 655(84%) 10(100%) 13(86.7%) 
Weight Loss 25(100%) 590(75.6%) 10(100%) 7(46.7%) 
Blurring of  vision 13(52%) 491(62.9%) 10(100%) 4(26.7%) 
Recurrent carbuncles (Boils) 9(36%) 79(10.1%) - - 
Pruritus vulvae  8(32%) 223(28.6%) - 15(100%) 
Coma 8(32%) 39(5.1%) - - 
Pancreatic calcification - - 10(100%) - 
Peripheral neuropathy  3(12%) 439(56.3%) - 7(46.7%) 
Erectile dysfunction  - 283(36.3%) - - 
Hypertension:  -    
*Antedated - 106(13.6%) - - 
*Simultaneously  - 197 (25.3%) - 5(33.3%) 
Retinopathy:     
*Background - 57(7.3%) - - 
*Proliferative  - - - - 
Nephropathy - 72(9.3%) - - 
Dietary (mono) therapy - 7(0.9%) - - 
Insulin therapy 25(100%) 176(22.6%) 10(100%) 15(100%) 
Oral Hypoglycaemic Agents (OHA) - 593 (76.0%) - - 
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hyperosmolar state and hypoglycaemia being the most 
14common cause of  death in the patients (39.8%) .
stNote: - i  DM 1  degree: Diabetes mellitus in first degree 
family member. (mother, father or siblings)
ii. Erectile dysfunction (ED): Defined as the inability to 
achieve and maintain erection sufficient enough to allow 
satisfactory sexual intercourse 
iii OHA: Oral Hypoglycaemic agent 
Priorities, Needs and Recommendations
The crucial issues arising from these Nigerian studies are: 
most Nigerians living with diabetes mellitus have suboptimal 
glycaemic control, are hypertensives, not meeting blood 
pressure and lipid targets and have chronic complications. 
Our present national aims and objectives towards improving 
diabetes care and prevention should focus on the following 
15priorities, needs and recommendations.
Improve health outcomes for people with diabetes.
Complications of  type 1 and type 2 diabetes can be prevented 
or significantly delayed. The essential medicines, diagnostic 
and monitoring technologies and education required are cost-
effective, but tragically inaccessible to many. A sustainable 
system to provide the essentials to people with diabetes is 
required. Development and appropriate use of  health 
services, especially primary care services, can avert costly 
end-stage complications and optimise the impact of  funds 
spent on healthcare.
The following recommendations are outlined to improve 
health outcomes of  people with diabetes:
Provide essential care to all people with diabetes
· Risk assessment and early diagnosis
· Access to essential low-cost medicines and supplies
· Self-care education
· Improve medicine-distribution systems
· Integrate diabetes and NCD care into health services for 
communicable diseases
Improve healthcare systems so that essential diabetes 
care can be reliably delivered
· Improve the training, continuing education and support 
of  health professionals
· Integrate training of  health work force, covering diabetes 
and related NCDs and infectious diseases
· Create shared record keeping systems to coordinate care 
over time and across caregivers
· Extend health services to all areas of  the country.
Provide care and support for people with diabetes 
complications
· Programmes for detection and management of  the 
complications of  diabetes
· Access to treatment, rehabilitation and social support for 
people who develop disabilities.
16Clinical Practice Guideline.
· Outpatient glycaemic, Lipid and Blood Pressure 
control: Achieving and maintaining good glycaemic 
control by treating-to-target, is the goal of  using 
guidelines. This is achieved by being proactive when 
glyceamic control is not at, or drifts away from acceptable 









Proportion of  patients 
achieving target, n (%) 
ADA Recommendation 
for adults with 
diabetes 
<7% 525 170 (32.4) 
IDF (Type 2) Target <6.5  489 100 (20.4) 
a 2 = 3.74       = 0.053 
N: number of  valid patient data used in the analysis 
n (%): number of  patients (percent patient)  
10Table  3: Diabcare Nigeria Multi-Centre Study  : 
Diabetes Complications by HbA  Categories1c
 N: number of  valid patient data used in the analysis
n (%): number of  patients (percent patient)
SD: standard deviation
MI/CABG/angioplasty: myocardial infarct/coronary angioplasty 
bypass graft/angioplasty
13Table 4: Prognostic Indices Of Diabetes mortality
 
Admission diagnosis      Frequency  
Hyperglycemic emergencies (HE)     82(40%)  
Poorly controlled blood pressure     44(21%)  
DM foot ulcers (DFU)      36(17.5%)  
Cerebrovascular disease (CVD)     20(9.8%)  
Hypoglycemia       7(3%)  
Peptic ulcer disease (PUD)       6(3%)  
Tropical hand ulcer (TDHS)     2(1%)  
Kochs disease       2(1%)  
Retroviral infection      1 (0.7%)  
Chronic renal failure      6(3%)  
TOTAL        206 (100%)  
13Table 5: Causes of Deaths In DM Subjects
Causes of death  %of total DM deaths  Case fatality rate 
HE     15(46%)   18% 
CVA      5(16%)    25% 
DFU     10(30%)   28% 
Hypoglycemia       1(3%)    14% 
CRF       1(3%)    16% 
Bleeding PUD      1(3%)    16% 
 HE=Hyperglycemic emergencies; CVA=Cerebral vascular accident; 
DFU=diabetic foot ulcer; CRF=chronic renal 
failure; PUD=peptic ulcer disease 
13Table 6: Morbidity and Mortality Data according to the Age Groups
Age Classes  DM admissions   Hypertension DM-related deaths
<34years  20(10%)    0   2(6%)
  35-64years  116(56%)   23(52%)   19(57.6%)
>65 years  70(34%)    21(48%)   12(36.4%)
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10Table 2: Diabcare Nigeria Multi-Centre Study : 
HbA  Levels Stratified by Different Guidelines1c
targets. The definitive action often required is prompt 
anti-hyperglycaemic treatment to the next step in the 
treatment Algorithm.
Out-patient Initiation of Basal Insulin (intermediate 
acting insulin) + Oral agents
· Basal Insulin is administered as a total daily dose at 
bedtime (22.00hrs)
· Dose calculation (titration) e.g.: (weight) 70kg x 0.2IU = 
14IU of  Insulin
· Continue SU at half  maximum dose & metformin at 2gm 
daily.
· Monitor effect of  bedtime Insulin by the fasting blood 
sugar
Out-patient Substitution Therapy with Pre-mixed Insulin 
(biphasic insulin) 
· If  control is not achieved with a total Basal Insulin 
(intermediate acting) dose of  25-30IU, switch patient to 
twice daily biphasic insulin
· Give 30min before breakfast and dinner.
· Sulphonylureas should be discontinued
· If  no contraindications Metformin can be continued if  
person is obese.
Annual Review
- Screening for proteinuria/microalbuminuria
- Screening for retinopathy
- Foot examination
- Education (as needed)
Prevent the Development of type 2 diabetes
The onset of  type 2 diabetes in people at high risk can be 
prevented or significantly delayed. This is cost-effective. 
Failure to invest in prevention strategies means that the 
number of  people with diabetes will continue to increase at 
unsustainable rates. The key modifiable risk factors for type 2 
diabetes which are physical inactivity, inappropriate nutrition 
and obesity  are not just a matter of  personal choice. 
Environments that encourage sedentary behaviour and high-
energy low-nutrient diets pose almost insurmountable 
barriers to healthy lifestyles. Such environments are found in 
all aspects of  our modern life  in work, in communities and in 
leisure.
The following recommendations are outlined to prevent the 
development of  type 2 diabetes:
Adopting a 'Health in All Policies' approach  
· Ensure all public policy sectors (education, transport, 
housing) protect and promote health
· Strengthen multi-stakeholder partnerships to prevent 
diabetes
Make healthy nutrition available to all - especially to 
pregnant women and children  
· Promote breastfeeding
· Promote healthy diet through education
· Control marketing and advertising of  unhealthy food 
and beverages
· Labeling food products
· Access to healthy food for disadvantaged population 
groups
· Promote physical activity through education
· Create adequate environments and facilities to promote 
physical activity
Consider a 'High-Risk' Prevention Programme where 
appropriate 
· Implement a prevention programme for people at high-
risk of  type 2 diabetes
Stop discrimination against people with diabetes
Millions of  people with diabetes face stigma and 
discrimination. This promotes a culture of  secrecy that can 
create barriers to services, employment, and even marriage, 
and may stop people with diabetes playing an active role in 
society. This burden is greater for children, indigenous 
peoples, ethnic minorities, women and the poor. Nobody 
should suffer discrimination and stigma because of  their 
diabetes. Action is required at international and national 
levels to ensure that the human rights of  people with or at risk 
of  diabetes are protected.
The following recommendations outlined to stop 
discrimination against people with diabetes:
Enable people with diabetes to claim their rights and 
responsibilities
· Sign an International Charter of  Rights for People with 
Diabetes
· Provide legal support and advice for people with diabetes
Increase public awareness of diabetes and reduce 
diabetes related stigma
· Develop information campaigns to raise awareness of  
diabetes and reduce stigma
· Identify and support high profile and community level 
champions of  diabetes
Empower people with diabetes to be at the centre of 
the diabetes response 
· Include people with diabetes in all phases of  diabetes 
16Table 7: Optimal Targets for Glycaemic, Lipid, Blood Pressure and Weight Control
Biochemical Index: 
Capillary blood glucose values (finger-prick) 
OPTIMAL  
   mmo1/L                    mg/dl 
Fasting  4-6 72-108                 
2-hour post-prandial 4-8                              72-144 
  
Glycated haemoglobin (HbA1c)  (%)                                    <7          
Weight BMI (kg/m2)                                    <25  
Blood Pressure (mmHg): 
Systolic                                     <130  
Diastolic                                      <80  




                                    <125  
                                     <75  
Lipids:                                                                                                ,mo1/L                        mg/d1 
Total cholesterol   <5.2                           <93.6 
LDL cholesterol   < 2.6                            < 46.8     
HDL cholesterol   >1.1                           >19.8 
Triglycerides     <1.7                      <30.6 
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policy and programme design
· Support the creation and capacity building of  
organisations and networks of  people with diabetes
The UN Summit on NCDs
The United Nations High-Level Summit on NCDs, which held 
in September 2011 was a unique opportunity to reverse the 
current diabetes and global NCD epidemic trends. In order 
for its recommendations to be successful, it is vital that world 
leaders commit to specific actions.  
The UN general assembly, the principal decision  making 
body of  the UN which represents all UN member states, held 
a UN summit on Non-communication Disease (NCD's) in 
order to bring global attention to these diseases and agreed on 
a plan of  action to address them part of  which includes;
1. Form and strengthen NCD alliance at local, national, 
regional and international levels with specific objectives.
2. IDF is leading the global diabetes community to 
maximize the opportunity of  the UN Summit on NCDs 
for diabetes. Our Member Associations are keys to the 
success of  this, in bringing global advocacy to the 
national and local level.
CONCLUSION
Most Nigerians living with diabetes have suboptimal 
glycaemic control, are hypertensives, not meeting blood 
pressure and lipid targets and have chronic complications. 
Improved quality of  care and treatment to targets is 
recommended to reduce diabetes related morbidity and 
mortality.
Our top national diabetes priorities should include:
· Equitable, universal access to care, essential medicines 
and supplies
· Prevent type 2 diabetes through healthy lifestyle 
promotion
· Development and implementation of  a National 
Diabetes Programme.
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Figure 1: Algorithm on the glycaemic management of T2DM
Adapted and modified from IDF clinical practice guideline 
for Type 2 Diabetes in Sub-Sahara Africa
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